Navigation Links
Eprodisate in Medical News

Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis

ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Company is taking new initiatives to pursue the drug development program for its investigational pr...

Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis

ECUBLENS, Switzerland, Dec. 14 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medi...

Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review

ECUBLENS, Switzerland, Dec. 6 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Company has received an acknowledgement from the United States Food and Drug Administration (FDA) tha...

BELLUS Health reports results for first quarter of fiscal 2009

...revenue (non-monetary liability) to accrued liability (monetary liability) following the recovery by the Company of ownership rights in and control of eprodisate (KIACTA(TM)). Other income amounted to $529,000 for the current quarter, compared to $278,000 for the same quarter the previous year. Other incom...

BELLUS Health reports results for the fourth quarter of 2008

...ement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product cand...ision to continue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the US Food...

BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update

...arily due to funds used in operating activities. eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis With respect to eprodisate (KIACTA(TM)), the Company submitted a proposed pro...II trial, should be sufficient to gain approval of eprodisate (KIACTA(TM)) for the treatment of AA Amyloidosis,....

BELLUS Health provides update on activities

...lic syndrome and Alzheimer's disease. The Company expects to file the Investigational New Drug application for the second Phase III clinical trial for eprodisate (KIACTA(TM)) for the treatment of Amyloid A amyloidosis in the fourth quarter of 2008. With respect to this second Phase III KIACTA(TM) clinical tri...

BELLUS HEALTH reports results for first quarter of fiscal 2008

...ement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product cand...ecision to pursue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Fo...

At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)

...also learn that Neurochem has regained full ownership rights and control on eprodisate (KIACTA(TM)) from Centocor Inc., a wholly owned subsidiairy of Johnson and ...ly announced, Neurochem will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Food and Drug Administratio...

Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives

...n July 2007 for the New Drug Application (NDA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis i... the marketing authorization application (MAA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis i...ts of costs reimbursable by Centocor in respect of eprodisate (KIACTA(TM))-related activities. The Company earns...
Eprodisate in Medical Technology

Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis

ECUBLENS, SWITZERLAND, June 07, 2007 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. , announces that the New England Journal of Medicine (NEJM) published the results of the "Eprodisate For AA Amyloidosis Trial" (EFAAT), recognize...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

...t Neurochem Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by th...
Other Tags
(Date:7/2/2015)... ... , ... ActiveBunch.com recently launched as a social network created for people with ... lifestyle community, Active Bunch allows users to connect with like-minded fitness enthusiasts from around ... or group events. , The spokesperson for Active Bunch explained the idea behind ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... with care and precision. There is an art and science that goes into ... of successfully reshaping the facial features and lives of more than 2,500 satisfied ...
(Date:7/2/2015)... ... July 02, 2015 , ... Five individuals from ... in Anniston for specialized disaster training. The team – composed of four clinicians ... California Hospital Association who attended the training, which is dedicated to preparing first ...
(Date:7/2/2015)... ... , ... After conducting a nationwide executive search led by healthcare ... Ariz., has hired Robert Trenschel, DO, as chief executive officer. A veteran physician executive ... his new duties at Yuma Regional Medical Center on July 13. , “Dr. Trenschel ...
(Date:7/2/2015)... ... 02, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that it has made two key appointments at its ... Manager at Catalent’s Schorndorf facility, which provides large scale, complex oral solid manufacturing ...
Breaking Medicine News(10 mins):Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 2Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 3Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
Other Contents